Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.Mos4.HIV Prime/Boost Regimens in Healthy Adults
NCT02935686Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2017
- Primary completion
- Nov 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
A Phase 2 trial of Ad26.Mos4.HIV in human immunodeficiency virus infection (HIV), sponsored by Janssen Pharmaceutical. Started Mar 2017; status: completed.
02
Drugs
Ad26.Mos4.HIV
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02935686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935686.